Tuberculosis Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Tuberculosis Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
Data On Investigational Drug TMC207 for Treatment of MDR-Tuberculosis, Published in New England Journal of Medicine
June 15th, 2009
Interim results from an ongoing phase 2, randomized, placebo-controlled trial of the investigational drug TMC207 for the treatment of multidrug-resistant tuberculosis (MDR-TB) were published in the New England Journal of Medicine today. TMC207 is being developed by Tibotec BVBA. The data show that the addition of TMC207 for eight weeks to a 5-drug background regimen, in patients with multidrug-resistant tuberculosis (MDR-TB), resulted in a significant increase in the proportion of patients achieving a negative sputum culture and a shorter time to sputum culture conversion compared with the background regimen alone. "The results of this study are highly encouraging news...
Source: Tuberculosis Week (2009-06-15)
|
